Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Xu

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
Genome Biology|December 24, 2021
Author Correction: The SEQC2 epigenomics quality control (EpiQC) studyJonathan Foox, Jessica Nordlund, Claudia Lalancette, et al.
Nature Biotechnology|September 7, 2023
Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materialsYuanting Zheng, Yaqing Liu, Jingcheng Yang, et al.
Bioanalysis|February 23, 2024
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard <u>(Part 3</u> - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization)Johanna Mora, Rachel Palmer, Leslie Wagner, et al.
Bioanalysis|January 25, 2025
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation <u>(PART 3A</u> - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sandra Prior, Sarah Wassmer, et al.
Scientific Reports|March 26, 2024
Extend the benchmarking indel set by manual review using the individual cell line sequencing data from the Sequencing Quality Control 2 (SEQC2) projectBinsheng Gong, Dan Li, Yifan Zhang, et al.
Bioanalysis|August 1, 2023
2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (<u>Part 3</u> - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)Luying Pan, Johanna Mora, Karl Walravens, et al.
Genome Biology|June 26, 2015
Comparison of RNA-seq and microarray-based models for clinical endpoint predictionWenqian Zhang, Ying Yu, Falk Hertwig, et al.
Bioanalysis|August 31, 2023
2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (<u>Part 1A</u> - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization <u>Part 1B</u> - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine)Matt Szapacs, Wenying Jian, Daniel Spellman, et al.
Genome Biology|April 17, 2021
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequencyWendell Jones, Binsheng Gong, Natalia Novoradovskaya, et al.
Nature Biotechnology|April 13, 2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncologyIra W Deveson, Binsheng Gong, Kevin Lai, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
Genome Biology|December 24, 2021
Author Correction: The SEQC2 epigenomics quality control (EpiQC) studyJonathan Foox, Jessica Nordlund, Claudia Lalancette, et al.
Nature Biotechnology|September 7, 2023
Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materialsYuanting Zheng, Yaqing Liu, Jingcheng Yang, et al.
Bioanalysis|February 23, 2024
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard <u>(Part 3</u> - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization)Johanna Mora, Rachel Palmer, Leslie Wagner, et al.
Bioanalysis|January 25, 2025
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation <u>(PART 3A</u> - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sandra Prior, Sarah Wassmer, et al.
Scientific Reports|March 26, 2024
Extend the benchmarking indel set by manual review using the individual cell line sequencing data from the Sequencing Quality Control 2 (SEQC2) projectBinsheng Gong, Dan Li, Yifan Zhang, et al.
Bioanalysis|August 1, 2023
2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (<u>Part 3</u> - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)Luying Pan, Johanna Mora, Karl Walravens, et al.
Genome Biology|June 26, 2015
Comparison of RNA-seq and microarray-based models for clinical endpoint predictionWenqian Zhang, Ying Yu, Falk Hertwig, et al.
Bioanalysis|August 31, 2023
2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (<u>Part 1A</u> - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization <u>Part 1B</u> - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine)Matt Szapacs, Wenying Jian, Daniel Spellman, et al.
Genome Biology|April 17, 2021
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequencyWendell Jones, Binsheng Gong, Natalia Novoradovskaya, et al.
Nature Biotechnology|April 13, 2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncologyIra W Deveson, Binsheng Gong, Kevin Lai, et al.
Pageof 17